WebbInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. La Jolla, California, United States 51-100 … Webb18 aug. 2024 · Funding Inhibrx has raised a total of $69.6M in funding over 4 rounds. Their latest funding was raised on May 21, 2024 from a Convertible Note round. …
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial …
WebbInhibrx, Inc. (INBX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 17.15 -0.21 (-1.21%) At close: 04:00PM EDT. 17.15 0.00 (0.00%) After … WebbInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated efficacy and safety... inhlakanipho consultants
Inhibrx Investors - SEC Filings
Webb12 okt. 2024 · 6/30/2024 9:00:00 AM Inhibrx Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105, a Novel Targeted 4-1BB Agonist, and Draws an Additional $60 Million from Oxford Finance (Press Release) 6/21/2024 10:53:27 AM Inhibrx Stock Gains 11% Webb9 nov. 2024 · As of November 9, 2024, Inhibrx had cash and cash equivalents of $141.1 million. R&D Expense. Research and development expenses were $18.5 million during … Webb16 juni 2024 · On June 15, 2024, Inhibrx, Inc. and Oxford Finance LLC entered into a fifth amendment to the Loan and Security Agreement between the Company and Oxford, dated as of July 15, 2024, as amended by the First Amendment dated November 12, 2024, the Second Amendment dated December 15, 2024, the Third Amendment dated June 18, … inhlanhla emhlophe umuthi